Close Menu

non-small cell lung cancer

In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.

ArcherDx plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

The institutes will send patients samples to Resolution Bioscience, which will sequence circulating tumor DNA to identify the genetic causes of drug resistance.

Qiagen's test detects the most frequently occurring somatic mutations in EGFR in less than four hours using real-time PCR on the Rotor-Gene Q platform.

The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.

Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.

A circulating tumor DNA analysis identified somatic mutations in more than 64 percent of advanced non-small cell lung cancer cases, including some drug targets.

The university will use the technology to screen blood samples for certain clinically actionable mutations in non-small cell lung cancer patients.

The partners will use a $5M NCI grant to add seven biomarkers to an EGFR electrochemical assay for non-small-cell lung-carcinoma.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.